GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » TheraCryf PLC (FRA:8EV) » Definitions » Loans Receivable

TheraCryf (FRA:8EV) Loans Receivable : €0.00 Mil (As of Sep. 2023)


View and export this data going back to 2018. Start your Free Trial

What is TheraCryf Loans Receivable?

TheraCryf's Loans Receivable for the quarter that ended in Sep. 2023 was €0.00 Mil.


TheraCryf Loans Receivable Historical Data

The historical data trend for TheraCryf's Loans Receivable can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

TheraCryf Loans Receivable Chart

TheraCryf Annual Data
Trend Mar14 Mar15 Mar16 Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23
Loans Receivable
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

TheraCryf Semi-Annual Data
Mar13 Mar14 Mar15 Sep15 Mar16 Sep16 Mar17 Sep17 Mar18 Sep18 Mar19 Sep19 Mar20 Sep20 Mar21 Sep21 Mar22 Sep22 Mar23 Sep23
Loans Receivable Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

TheraCryf Loans Receivable Calculation

Loans Receivable are the funds that a company has lent but have not yet been repaid.


TheraCryf Loans Receivable Related Terms

Thank you for viewing the detailed overview of TheraCryf's Loans Receivable provided by GuruFocus.com. Please click on the following links to see related term pages.


TheraCryf (FRA:8EV) Business Description

Traded in Other Exchanges
Address
Congleton Road, Suite 24G13- Block 24, Alderley Park, Nether Alderley, GBR, SK10 4TG
Evgen Pharma PLC is a UK-based clinical-stage drug development company. The company is focused on the development of sulforaphane-based compounds. Its core technology is Sulforadex, which synthesis and stabilizes the naturally occurring compound sulforaphane. Geographically, the company operates only in the United Kingdom. It is engaged in the treatment of breast cancer and Subarachnoid Haemorrhage.

TheraCryf (FRA:8EV) Headlines

No Headlines